-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Gene Replacement and Targeted Genome Editing in Hematopoietic Stem Cells for the Treatment of Human Diseases

Program: General Sessions
Session: Presidential Symposium
Tuesday, December 8, 2015, 9:45 AM-11:15 AM
Hall D, Level 2 (Orange County Convention Center)

Luigi Naldini, MD, PhD

San Raffaele University, San Raffaele Telethon Institute for Gene Therapy, Milan, Italy

Disclosures: Naldini: Biogen: Research Funding ; Sangamo Biosciences: Research Funding ; GlaxoSmithKline: Other: GSK licensed gene therapies developed at my Institute and the Institute receives milestone payments ; San Raffaele Telethon Institute: Patents & Royalties: Lentiviral vector technology ; Salk Institute: Patents & Royalties: Lentiviral vectors ; Genenta Sciences: Equity Ownership , Membership on an entity’s Board of Directors or advisory committees .

See more of: Presidential Symposium
See more of: General Sessions
<< Previous Presentation | Next Presentation